U.S. Markets closed

Synthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher

Zacks Equity Research

Synthetic Biologics, Inc. SYN was a big mover last session, as the company saw its shares rise nearly 8% on Friday. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company — as the stock is now up 47.5% in the past one-month time frame.

The company has not seen any estimate revisions over the past one month, while the Zacks Consensus Estimate for the current quarter also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Synthetic Biologics currently has a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.

Synthetic Biologics, Inc Price

Synthetic Biologics, Inc Price | Synthetic Biologics, Inc Quote

Another stock worth considering in the Medical - Biomedical and Genetics sector is Alexion Pharmaceuticals, Inc. ALXN, which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is SYN going up? Or down? Predict to see what others think: Up or Down

New Report: An Investor’s Guide to Cybersecurity

Cyberattacks have become more frequent and destructive than ever. In fact, they’re expected to cause $6 trillion per year in damage by 2020.

The cybersecurity industry is expanding quickly in response to these threats. In fact, a projected $170 billion per year will be spent to protect consumer and corporate assets. Zacks has just released Cybersecurity: An Investor’s Guide to Locking Down Profits which reveals 4 promising investment candidates.

Download the new report now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
Synthetic Biologics, Inc (SYN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research